Taltz is a biological medicine used to treat several inflammatory conditions. **Plaque psoriasis** Taltz is used to treat people aged 6 years and older weighing at least 25 kg with moderate-to-severe plaque psoriasis, a disease causing red, scaly patches on the skin. It is used when people require systemic treatment (treatment with medicines affecting the whole body). **Psoriatic arthritis** Taltz is used to treat adults and children aged 6 years and older weighing at least 25 kg with psoriatic arthritis (when psoriasis causes inflammation of the joints) whose disease is causing symptoms and has not improved sufficiently with other medicines called disease-modifying anti-rheumatic drugs (DMARDs) or who cannot use them. Taltz is used alone or with another medicine called methotrexate (a medicine that acts on the immune system). **Axial spondyloarthritis** Taltz is used to treat adults with axial spondyloarthritis, an inflammation of the spine causing back pain and stiffness. It can be used in people with the radiographic form of the disease, also called ankylosing spondylitis (when bone damage is visible on X-rays), and when standard treatments have not worked well enough. It can also be used in those with the non-radiographic form (where no bone damage is visible on X-rays) who show signs of inflammation, such as elevated levels of C-reactive protein (CRP) or signs seen on magnetic resonance imaging (MRI), and for whom non-steroidal anti-inflammatory drugs (NSAIDs) have not worked well enough. **Enthesitis-related arthritis** Taltz is used to treat children aged 6 years and older who weigh at least 25 kg with enthesitis-related arthritis, when their condition has not improved sufficiently with standard treatments or who cannot use them. Enthesitis-related arthritis is an inflammation of the joints and entheses (areas where tendons and ligaments attach to bone). Taltz is used alone or with methotrexate. Taltz contains the active substance ixekizumab.
Therapeutic Indication
### Therapeutic indication Plaque psoriasis Taltz is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Paediatric plaque psoriasis Taltz is indicated for the treatment of moderate to severe plaque psoriasis in children from the age of 6 years and with a body weight of at least 25 kg and adolescents who are candidates for systemic therapy. Psoriatic arthritis Taltz, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies. Axial spondyloarthritis Ankylosing spondylitis (radiographic axial spondyloarthritis) Taltz is indicated for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy. Non-radiographic axial spondyloarthritis Taltz is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs). Juvenile idiopathic arthritis (JIA) Juvenile psoriatic arthritis (JPsA) Taltz, alone or in combination with methotrexate, is indicated for the treatment of active JPsA in patients 6 years of age and older and with a body weight of at least 25 kg, who have had an inadequate response to, or who are intolerant of, conventional therapy. Enthesitis-related arthritis (ERA) Taltz, alone or in combination with methotrexate, is indicated for the treatment of active ERA in patients 6 years of age and older and with a body weight of at least 25 kg, who have had an inadequate response to, or who are intolerant of, conventional therapy.
Therapeutic Area (MeSH)
ATC Code
L04AC13
ATC Item
ixekizumab
Pharmacotherapeutic Group
Immunosuppressants
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| ixekizumab | N/A | 依奇珠单抗 |
EMA Name
Taltz
Medicine Name
Taltz
Aliases
N/A
